PT103069A - Forma farmaceutica de toxicidade reduzida para administracao por via oral de indometacina - Google Patents

Forma farmaceutica de toxicidade reduzida para administracao por via oral de indometacina

Info

Publication number
PT103069A
PT103069A PT103069A PT10306904A PT103069A PT 103069 A PT103069 A PT 103069A PT 103069 A PT103069 A PT 103069A PT 10306904 A PT10306904 A PT 10306904A PT 103069 A PT103069 A PT 103069A
Authority
PT
Portugal
Prior art keywords
administration
pharmaceutical form
reduced toxicity
indometacin
oral
Prior art date
Application number
PT103069A
Other languages
English (en)
Inventor
Antonio Manuel Silveri Cabrita
Ana Cristina Da Costa Rib Rama
Francisco Jose De Baptis Veiga
Isabel Vitoria Neves D Pereira
Maria Margarida Duart Caramona
Adriano Teixeira Barbosa Sousa
Original Assignee
Univ De Coimbra
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ De Coimbra filed Critical Univ De Coimbra
Priority to PT103069A priority Critical patent/PT103069A/pt
Priority to PCT/PT2005/000003 priority patent/WO2005074992A1/en
Publication of PT103069A publication Critical patent/PT103069A/pt

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B82NANOTECHNOLOGY
    • B82YSPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404Indoles, e.g. pindolol
    • A61K31/405Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • A61K49/0004Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1629Organic macromolecular compounds
    • A61K9/1652Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nanotechnology (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pathology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
PT103069A 2004-02-10 2004-02-10 Forma farmaceutica de toxicidade reduzida para administracao por via oral de indometacina PT103069A (pt)

Priority Applications (2)

Application Number Priority Date Filing Date Title
PT103069A PT103069A (pt) 2004-02-10 2004-02-10 Forma farmaceutica de toxicidade reduzida para administracao por via oral de indometacina
PCT/PT2005/000003 WO2005074992A1 (en) 2004-02-10 2005-02-09 Pharmaceutical form of reduced toxicity for oral administration of indomethacin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PT103069A PT103069A (pt) 2004-02-10 2004-02-10 Forma farmaceutica de toxicidade reduzida para administracao por via oral de indometacina

Publications (1)

Publication Number Publication Date
PT103069A true PT103069A (pt) 2005-08-31

Family

ID=34836915

Family Applications (1)

Application Number Title Priority Date Filing Date
PT103069A PT103069A (pt) 2004-02-10 2004-02-10 Forma farmaceutica de toxicidade reduzida para administracao por via oral de indometacina

Country Status (2)

Country Link
PT (1) PT103069A (pt)
WO (1) WO2005074992A1 (pt)

Also Published As

Publication number Publication date
WO2005074992A1 (en) 2005-08-18

Similar Documents

Publication Publication Date Title
DK1940467T3 (da) Lægemiddelsammensætning med langvarig frigivelse
BRPI0616703A2 (pt) forma de dosagem farmacêutica
NO20075628L (no) Farmasøytiske formuleringer
ATE532788T1 (de) Pharmazeutische verbindungen
BRPI0810646A2 (pt) " compostos farmacêuticos ".
RU2398586C3 (ru) Фармацевтическая композиция
ITBO20050123A1 (it) Formulazioni farmaceutiche gastroresistenti contenenti rifaximina
FR2881652B1 (fr) Forme pharmaceutique orale microparticulaire anti-mesuage
FR2892937B1 (fr) Forme pharmaceutique orale microparticulaire anti-mesusage
BRPI0511900A (pt) composições farmacêuticas
IL191907A0 (en) Azepinoindole derivatives as pharmaceutical agents
NO20053119D0 (no) Farmasoytiske sarmmensetninger med fentanyl for intranasal administrasjon.
PL1957073T3 (pl) Substancja lecznicza
ITMO20050343A1 (it) Supporto per medicazione
BRPI0719880A2 (pt) Forma de dosagem sólida farmacêutica para administração oral e método para preparar a mesma.
ATE483702T1 (de) Neue pharmazeutische verbindungen
BRPI0812964A2 (pt) Forma de dosagem farmacêutica oral sólida
EP1941896A4 (en) COMPOSITION CONTAINING A DIPEPTIDE FOR ORAL ADMINISTRATION
FI20041129A0 (fi) Tioksotiatsolidinoniyhdisteitä lääkkeinä käytettäviksi
BRPI0918539A2 (pt) preparação farmacêutica sólida para administração oral
HUP0500683A3 (en) New arylpiprazole salts for producing pharmaceutical composition
ITMI20051826A1 (it) Kit per la somministrazione parenterale di medicamenti
HK1092734A1 (en) Oral formulation for twice-daily administration
ITMI20041447A1 (it) Composizione farmaceutica comprendente gabapentina
PT103069A (pt) Forma farmaceutica de toxicidade reduzida para administracao por via oral de indometacina

Legal Events

Date Code Title Description
BB1A Laying open of patent application

Effective date: 20040415

MM3A Annulment or lapse

Effective date: 20060810

NF3A Restitutio in integrum

Free format text: RESTITUTIO IN INTEGRUM

Effective date: 20070302

FC3A Refusal

Effective date: 20070615